The World Health Organisation today revealed that dexamethasone should only be used to treat severely-ill COVID-19 patients. The Director-General, WHO, Dr. Tedros Adhanom Ghebreyesus said those with mild COVID-19 cases should not use the drug.He added that people who are not infected should not take the drug as there is no proof the drug is effective in preventing COVID-19 infection. According to the WHO chief, dexamethasone should only be used for patients with severe or critical case of COVID-19, under close clinical supervision.
“There is no evidence this drug works for patients with mild disease or as a preventative measure, and it could cause harm. Ghebreyesus said the recent finding that the steroid dexamethasone has life-saving potential for critically ill-COVID-19 patients gave a much-needed reason to celebrate.He, however, said “the next challenge is to increase production rapidly and equitably distribute dexamethasone worldwide, focusing on where it is needed most. “Demand has already surged, following the UK trial results showing dexamethasone’s clear benefit. “Fortunately, this is an inexpensive medicine and there are many dexamethasone manufacturers worldwide, who we are confident can accelerate production.”
The WHO chief said countries must work together to ensure supplies are prioritised for countries where there are large numbers of critically-ill patients, and that supplies remain available to treat other diseases for which it is needed.“Transparency and constant monitoring will be key to ensuring needs dictate supplies, rather than means. “It is also important to check that suppliers can guarantee the quality, as there is a high risk of substandard or falsified products entering the market. He urged countries to be careful and creative in finding solutions that enable people to stay safe while getting on with their lives.Photo Credit: Getty